0001209191-22-016526.txt : 20220304
0001209191-22-016526.hdr.sgml : 20220304
20220304205802
ACCESSION NUMBER: 0001209191-22-016526
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220301
FILED AS OF DATE: 20220304
DATE AS OF CHANGE: 20220304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sepp-Lorenzino Laura
CENTRAL INDEX KEY: 0001777421
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 22716014
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS, INC.
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2022-03-01
2022-03-03
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001777421
Sepp-Lorenzino Laura
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Scientific Officer
Stock Option (right to buy)
79.85
2022-03-01
4
A
0
20203
0.00
A
2032-02-28
Common Stock
20203
20203
D
The original Form 4 incorrectly reported the number of options granted as 13,816.
This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
/s/ James Basta, attorney-in-fact
2022-03-04